• Agios Pharmaceuticals recently prepared to report its March 2026 quarter results, with analysts expecting a loss but anticipating higher year-over-year revenue and having revised consensus EPS estimates upward over the prior month.
• Despite an Earnings ESP signal pointing to a possible negative surprise, Agios had outperformed EPS expectations in three of the last four quarters, drawing investor attention to whether that pattern could continue.
• Next, we’ll examine how the recent EPS estimate revisions and earnings expectations may shape Agios Pharmaceuticals’ broader investment narrative.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Agios Pharmaceuticals Investment Narrative Recap

To own Agios, you have to believe its bet on mitapivat across rare blood disorders can eventually outweigh today’s recurring losses and high spending. The latest earnings setup, with a likely quarterly loss but improved revenue expectations, does not materially change the near term focus on thalassemia and sickle cell expansion as the key catalyst, nor does it ease the central risk that PYRUKYND’s uptake or safety profile could fall short of expectations.

The most relevant recent announcement is Agios’s March 31, 2026 update that it plans to seek U.S. accelerated approval for mitapivat in sickle cell disease, with a confirmatory trial requested by the FDA and operating expenses guided to remain flat. This development ties directly into the upcoming earnings report, since any hints on regulatory timing, further trial commitments, or commercial planning for sickle cell could color how investors interpret near term losses against the longer term revenue opportunity.

Yet beneath that opportunity, investors should be aware of the growing concern around hepatocellular injury risk and how it could...

Agios Pharmaceuticals' narrative projects $371.8 million revenue and $54.9 million earnings by 2029. This requires 90.2% yearly revenue growth and about a $468 million earnings increase from -$412.8 million today.

Uncover how Agios Pharmaceuticals' forecasts yield a $41.50 fair value, a 61% upside to its current price.

Exploring Other Perspectives

While consensus sees steady but costly growth tied to PYRUKYND, the most optimistic analysts once projected about 125% annual revenue growth and US$65.9 million earnings by 2028, highlighting how views on Agios’s narrow drug dependence and regulatory exposure can diverge sharply, and how this new earnings and safety context might shift those expectations.

Explore 2 other fair value estimates on Agios Pharmaceuticals - why the stock might be worth over 7x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Agios Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agios Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 54 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.